TFX Teleflex Incorporated

Teleflex now offers its Titan SGS™ Stapler with Staple Line Reinforcement

Teleflex now offers its Titan SGS™ Stapler with Staple Line Reinforcement

A New Choice for Bariatric Surgeons: 

Titan SGS Standard Staple Line Reinforcement 

with GORE® SEAMGUARD® Bioabsorbable Staple Line Reinforcement

WAYNE, Pa., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced that the Titan SGS Stapler—the only purpose-built stapler for gastric tissue with a specific indication for sleeve pouch creation in bariatric procedures1—is now available with staple line reinforcement (SLR). This new option is designed to offer a choice for bariatric surgeons who prefer buttressing on every staple fire during sleeve gastrectomy. The Titan SGS Standard Staple Line Reinforcement received FDA 510(k) clearance on October 6, 2023,2 and is available for pre-order.

This buttressing combines the strengths of the Titan SGS Stapler with the confidence of GORE® SEAMGUARD® Bioabsorbable Staple Line Reinforcement Material and is designed to support staple line strength3 and help reduce leaks or bleeds.1,4-7 The Titan SGS Stapler is a 23cm, single-fire stapler designed to deliver more consistent and symmetrical sleeve anatomy by enabling the Standard Sleeve Technique, an anatomy-based approach to sleeve gastrectomy.1 GORE® SEAMGUARD® Reinforcement Material is the only*5 staple line reinforcement proven to significantly reduce leaks in sleeve gastrectomy procedures.4 This complimentary pairing supports bariatric surgeons. “Our focus is to provide bariatric surgeons with innovative solutions for sleeve gastrectomy. Our Titan SGSStandard Staple Line Reinforcement featuring GORE® SEAMGUARD® Reinforcement Material expands device selection for surgeons. This FDA clearance means that surgeons who prefer staple line reinforcement now have that option with the Titan SGS Stapler,” said James Ferguson, President and General Manager, Surgical, Teleflex Incorporated.

More than 10,000 sleeve gastrectomy procedures—laparoscopic and robotic-assisted—have been completed across the United States using the Titan SGS Stapler since its introduction to the market in 2021. Dr. Christina Sanders was the first surgeon to utilize the Staple Line Reinforcement and noted "The Titan SGS™ Stapler along with the Standard Staple Line Reinforcement helps support the security of the staple line and outcomes from my patients."

Product Highlights

  • Designed to protect against leaks. GORE® SEAMGUARD® Reinforcement Material has less than 0.39% leak rate in the U.S.5
  • Engineered to protect against bleeding. The buttress conforms to the staple line anatomy and provides a matrix for blood to start clotting.3 This is designed to support the Titan SGS Stapler’s anatomy-based approach to sleeve gastrectomy.
  • Designed to reduce bleeding complications. Randomized prospective data shows that GORE® SEAMGUARD® Reinforcement Material significantly reduces bleeding in standard and laparoscopic gastric bypass.6,7

For more information about the Titan SGS Standard Staple Line Reinforcement featuring GORE® SEAMGUARD® Reinforcement Material, or to learn more about the Titan SGS Stapler or the Standard Sleeve Technique, visit .

*Considering all systematic review and meta-analysis of published articles only that distinguish between types of staple line reinforcement as of January 2024.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular access, interventional cardiology and radiology, anesthesia, emergency medicine, surgical, urology and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit .

Teleflex is the home of Arrow™, Deknatel™, LMA™, Pilling™, QuikClot™, Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose.

About W. L. Gore & Associates, Inc.

W. L. Gore & Associates is a global materials science company dedicated to transforming industries and improving lives. Since 1958, Gore has solved complex technical challenges in demanding environments — from outer space to the world’s highest peaks to the inner workings of the human body. With more than 10,500 Associates and a strong, team-oriented culture, Gore generates annual revenues of $4 billion. GORE and SEAMGUARD are trademarks of W. L. Gore & Associates. Visit: .

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

Teleflex, the Teleflex logo, Arrow, Deknatel, LMA, Pilling, QuikClot, Rüsch, Standard Sleeve, Titan SGS, UroLift, and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries.

© 2023 Teleflex Incorporated. All rights reserved.

References:

1. 510(k) No. K210278. The Titan SGS linear cutter is intended for longitudinal transection and resection of gastric tissue for sleeve gastrectomy pouch creation. 2021. Database Product Search (March 2023, Product Code: GDW).

2. Received FDA 510(k) clearance on October 6, 2023, classified as a class II device with the trade name Standard Staple-Line Reinforcement (SSLR23). 510(k) number K231603.

3. McCrea C. GORE® SEAMGUARD® Reinforcement Product Family: Relationship between Design Inputs and “Engineered to reduce the incidence of perioperative leaks and bleeding” Marketing Statement. Flagstaff, AZ; 2015. [Work plan]. WP107241

4. Gagner M, Kemmeter P. Comparison of laparoscopic sleeve gastrectomy leak rates in five staple-line reinforcement options: a systematic review. Surgical Endoscopy 2020;34(1):396-407 3

5. Data on file 2022; W. L. Gore & Associates, Inc; Flagstaff, AZ.

6. Miller KA, Pump A. Use of bioabsorbable staple reinforcement material in gastric bypass: a prospective randomized clinical trial. Surgery for Obesity & Related Diseases 2007;3(4):417-422

7. Nguyen NT, Longoria M, Welbourne S, Sabio A, Wilson SE. Glycolide copolymer staple-line reinforcement reduces staple site bleeding during laparoscopic gastric bypass. A prospective randomized trial. Archives of Surgery 2005;140(8):773-778.

Contacts:

Teleflex

Lawrence Keusch

Vice President, Investor Relations and Strategy Development

      

610-948-2836



EN
09/01/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Teleflex Incorporated

 PRESS RELEASE

Teleflex Publishes 2023 Global Impact Report

Teleflex Publishes 2023 Global Impact Report Highlights Accomplishments and Sets Goals for Corporate Social Responsibility Program WAYNE, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it has published its 2023 Global Impact Report. The report outlines recent accomplishments and sets new targets to support the company’s Corporate Social Responsibility (CSR) program and aligns with the Global Reporting Initiative (GRI), the Sustainability Accounting Standards Board (SASB), and Taskforce on Climat...

 PRESS RELEASE

Teleflex Expands Intraosseous Vascular Access Portfolio with New Arrow...

Teleflex Expands Intraosseous Vascular Access Portfolio with New Arrow™ EZ-IO™ Intraosseous Access Procedure Tray The First and Only Sterile, Single-Use IO Tray Cleared by the U.S. Food and Drug Administration WAYNE, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a global leader in medical technologies and pioneer in intraosseous vascular access, today announced the launch of the Arrow™ EZ-IO™ Intraosseous Access Procedure Tray. This sterile, single-use tray includes all the components required for the IO access procedure, enabling a streamlined clinician workf...

 PRESS RELEASE

Outcomes From Two New Head-to-Head Randomized Controlled Trials Involv...

Outcomes From Two New Head-to-Head Randomized Controlled Trials Involving the UroLift™ System Highlight a Superior Patient Experience* Against Rezūm and Its Advantage Over Medical Therapy as an Early Intervention for BPH WAYNE, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a global leader in medical technologies, today announced the presentation of new research findings from the 2024 American Urological Association Annual Meeting in San Antonio, TX, May 3 – 6, 2024, showcasing excellent patient experience* with the Prostatic Urethral Lift (PUL) with the UroLift™...

 PRESS RELEASE

Teleflex Announces Quarterly Dividend

Teleflex Announces Quarterly Dividend WAYNE, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable June 14, 2024, to shareholders of record at the close of business on May 15, 2024. Additional information about Teleflex can be obtained from the company’s website at . About Teleflex Incorporated Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We ...

 PRESS RELEASE

Teleflex Reports First Quarter Financial Results and Full Year 2024 Ou...

Teleflex Reports First Quarter Financial Results and Full Year 2024 Outlook WAYNE, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the first quarter ended March 31, 2024. First quarter financial summary Revenues of $737.8 million, up 3.8% compared to the prior year period; up 3.8% on a constant currency basisGAAP diluted EPS from continuing operations of $0.33, compared to $1.63 in the prior year periodAdjusted diluted EPS from continuing operations of $3.21, compared to $3.09 in the prior year period 2...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch